Sharda Cropchem FY26: Margin expansion and record PAT as Europe leads growth

Sharda Cropchem closed FY26 with its strongest financial performance as a listed company. On a consolidated basis, revenue from operations rose 22% year-on-year to INR 5,268 crore. Operating leverage showed up sharply in profitability. EBITDA grew 69% to INR 1,040 crore and PAT more than doubled to INR 681 crore, up 124% from FY25.

The year was also notable for margin recovery. Gross margin expanded to 35.9% in FY26 from 29.9% in FY25. EBITDA margin improved to 19.7% from 14.2%. In Q4 FY26, revenue grew 13% to INR 2,065 crore, while EBITDA jumped 75% to INR 513 crore and PAT rose 57% to INR 319 crore. Gross margin in Q4 improved to 37.3%.

What drove FY26 performance: volume, FX, and mix

Management provided a bridge for revenue growth, helping separate what was operational from what was macro-driven. For FY26, volume growth was stated at 13.4%, FX impact at plus 10.3%, and price and product mix impact at minus 1.8%, adding up to roughly 21.9% overall growth. For Q4 FY26, volume growth was 4.3%, FX impact was plus 11.7%, and price and mix impact was minus 3.0%.

The message from management was that demand conditions improved, distribution inventories normalised, and pricing showed gradual recovery. However, the quantitative split also indicates that currency movements were a meaningful tailwind in reported growth.

FY26 and Q4 FY26 financial snapshot

Business mix: agrochemicals dominate, Europe dominates agrochemicals

Sharda Cropchem’s business remains largely agrochemical-led. In FY26, the agrochemical segment reported revenue of INR 4,717 crore, up 25% YoY, while the non-agrochemical segment was INR 551 crore, up 1% YoY. In Q4 FY26, agrochemicals grew 14% YoY to INR 1,927 crore, while non-agrochemicals were flat at INR 138 crore.

Within agrochemicals, the company’s portfolio spans herbicides, insecticides and fungicides. For FY26, herbicides were INR 2,410 crore, insecticides INR 1,005 crore, and fungicides INR 1,302 crore. In Q4 FY26, herbicides were INR 896 crore, insecticides INR 361 crore, and fungicides INR 669 crore.

Geographically, Europe was the largest region. In FY26, Europe contributed INR 2,981 crore of agrochemical revenue, presented as 63% of agrochemicals, and grew 37% YoY. NAFTA contributed INR 1,266 crore (27%) and grew 3%. LATAM was INR 254 crore (5%) and grew 33%. RoW was INR 216 crore (5%) and grew 21%. In Q4 FY26, Europe’s share rose to 70% of agrochemical revenue.

Management also shared regional gross margins on the concall. Europe gross margin was cited at about 42% to 42.5% for the full year, while NAFTA and LATAM were cited at 25% for the year. RoW was cited at 43% for the year.

Strategy focus: registrations and forward integration in sales

The company positions itself as an IP-driven marketer and distributor in crop protection chemicals. The investor presentation reiterates an asset-light model where manufacturing is outsourced, while Sharda focuses on identifying generic molecules, developing dossiers, obtaining registrations, and selling through distributors and a growing in-house sales force.

As of March 31, 2026, Sharda reported 3,011 registrations and 1,004 applications pending globally. Management repeatedly highlighted that timelines for registrations can be uncertain due to changing regulatory requirements, field trials, and the cadence of regulator meetings.

The stated way forward includes building the sales force (forward integration), expanding distribution presence, continual investment in registrations, and a sharper focus on operational efficiencies and cost management.

Balance sheet and cash flow: debt-free with higher liquidity, but receivables remain elevated

Sharda ended FY26 with a reported cash, bank and liquid investments balance of INR 702 crore. Total equity was reported at INR 3,137 crore and the company stated it remains debt-free.

Working capital days improved to 98 days as of March 31, 2026 from 118 days a year earlier. The improvement was driven mainly by lower inventory days (72 vs 83) and higher creditor days (125 vs 111), while receivable days increased to 151 from 146.

The cash flow statement shows net cash from operating activities of INR 655.7 crore in FY26, while net cash used in investing activities was INR 513.1 crore. Management reported FY26 capex of INR 505 crore.

The company also announced shareholder payout. The Board recommended a final dividend of INR 9 per equity share, and along with the interim dividend of INR 6 per share paid earlier, the total dividend for FY26 aggregates to INR 15 per share.

FY27 outlook: moderate growth guidance with margin maintenance

Management guided for FY27 revenue growth of about 10% to 15%. It guided gross margins to remain around 35% plus or minus a few percentage points, and EBITDA margins in the range of 18% to 20%. CFO indicated an effective tax rate expectation of 18% to 20%.

On operational risks linked to geopolitics, sourcing and logistics, management stated on the call that there were no major challenges in sourcing from China due to the war situation and that any logistics delays and cost increases were insignificant. It also said freight routes were not going through the sensitive Middle East corridor discussed in the call, and that shipments were going via south of Africa, increasing transit time but not jeopardising supply.

Takeaways

FY26 numbers reflect a sharp profitability rebound for Sharda Cropchem, supported by stronger volumes, a material FX tailwind, and a step-up in gross margins. Europe continues to be the growth engine and the biggest concentration point.

The FY27 guidance sets expectations for more moderate top-line growth but aims to defend the margin gains. The key variables to track from here are the sustainability of gross margin around the mid-30s, working capital discipline given elevated receivable days, and the pace and monetisation of its large registration base and pipeline.